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Progression through G1 phase of the cell cycle is controlled largely by growth 
factors in early G1 and by nutrients in late G1 indicating sufficient raw material for cell 
division. We previously mapped a late G1 cell cycle checkpoint for lipids upstream from 
a mammalian target of rapamycin complex 1 (mTORC1)-mediated checkpoint and 
downstream from a mid-G1 checkpoint known as the Restriction point. We therefore 
investigated a role for lipids in progression through late G1 into S-phase. Quiescent BJ-
hTERT human fibroblasts primed back into G1 with FBS treatment, were treated with a 
mixture of lipids and carrier bovine serum albumin (BSA) along with [3H]-thymidine 
deoxyribose ([3H]-TdR) to monitor progression into S-phase. Surprisingly, BSA by itself, 
was more effective than FBS in promoting progression to S-phase – the lipids had no 
impact on progression. While insulin strongly stimulated mTORC1 activity, it did not 
impact [3H]-TdR incorporation. We show that though BSA only sustained low levels of 
mTORC1 activity, rapamycin strongly inhibited BSA-induced progression to S-phase. 
BSA treatment promoted mitosis evident from an increase in cell number after 
treatment, but not progression through a second G1. Thus, after priming quiescent cells 
with FBS, albumin was sufficient to promote progression into S-phase. The BSA did not 
compensate as a source of free amino acids in that amino acids were present in the 
culture media and additional increasing doses of exogenous amino acids did not affect 
DNA synthesis. We propose that the presence of albumin – the most abundant protein 
in serum – signals to the cell a broader availability and variety of amino acids over 
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The mammalian cell cycle is the carefully ordered sequence of events that allows 
a cell to grow, replicate its genome and divide into two daughter cells. It comprises four 
phases: Gap 1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M). During G1 the cell 
grows in size and prepares itself for DNA replication. In S phase, DNA replication 
occurs and G2 is where the cell continues to grow and prepares for mitosis. Lastly, the 
completion of mitosis results in two identical daughter cells (Poon, 2016). Successful 
completion of each of these phases requires passage through various checkpoints 
where the cell assesses availability of sufficient nutrients and proper growth. These 
checkpoints include the growth factor regulated restriction checkpoint (R) in G1, the 
DNA damage checkpoint in S and G2 and the spindle assembly checkpoint in Mitosis.  
Consistent with the importance of G1 regulation, most significant driver mutations 
in cancer are in genes that regulate passage through G1 (Hanahan and Weinberg, 
2011). This includes activating mutations in genes encoding a group of proteins called 
cyclin dependent kinases (CDK). CDK activation plays a crucial role in every phase of 
the cycle and is controlled by upstream growth factor signaling (Otto and Sicinski, 
2017). In G1 in particular CDK4/6 as well as later CDK2 activation leads to 
phosphorylation of Retinoblastoma protein (Rb) (Figure 1.1). This in turn allows for 
liberation of E2F, a transcription factor that initiates progression from G1 into S phase. 
However, as mentioned earlier, for the activation of CDKs to occur, the current 
understanding is that upstream mitogenic factors must be present to initiate 
transcription of the very cyclins that CDKs complex with for activity. These include 
factors such as platelet derived growth factor (PDGF), epidermal growth factor (EGF) 
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and insulin-like growth factor-1 (IGF-1). Growth factor availability therefore is thought to 
be crucial for successful passage through G1.   
G1 itself can be divided into two parts, early and late which are separated by the 
restriction point (R). Availability of growth factors at this point, mapped to approximately 
3.5 hrs. into G1, will allow the cell to continue to late G1, whereas absence of growth 
factors results in the exit of the cycle into a phase known as G0 (Foster et al., 2010). Re-
entry into the cycle from G0 may occur with the reintroduction of growth factors. Once 
passed the restriction point into late G1 there are additional nutrient requirements for 
entry into S phase (Saqcena et al., 2013).  
 




mTOR and nutrient checkpoints 
Previously, our lab has mapped distinct nutrient checkpoints in late G1, namely 
the essential amino acid, glutamine and lipid checkpoints (Patel et al., 2017; Saqcena et 
al., 2013). Deprivation of any of these nutrients from the cell culture media led to an 
acute late-G1 arrest in normal human fibroblast cells, BJ-hTERT. The cells were 
subjected to an initial cell cycle block which entailed 48 hrs. in media in which one 
serum component was missing, followed by reintroduction of that component but 
withdrawal of another for 24 hours. In these 24 hrs. cells were also given radiolabeled 
thymidine to assess whether they were able to progress to S phase to synthesize new 
DNA and incorporate this radioactive label. This method allowed us to determine which 
nutrient, growth factors, essential amino acids, glutamine, or lipids within serum, are 
taken inventory of by the cell relative to one another (Figure 1.2). 
From that data it was concluded that essential amino acids, glutamine then fatty 
acid (FA) availability are assessed before the cell is allowed to journey further through 
G1. In addition to this, there seems to be an even later checkpoint mediated by the 
activation of mammalian target of rapamycin (mTOR), a serine threonine kinase crucial 
for cell growth that serves as a nutrient and energy sensor in the cell. It is well known 
that amino acids themselves are required for activation of mTOR and our lab has also 
shown the potential for lipids to activate mTOR (Patel et al., 2017). However, it seems 
that total inactivation of mTOR with high dose Rapamycin, an inhibitor of mTOR, causes 
these cells to arrest after all three of the previous checkpoints. This suggests some level 
of redundancy for assessing availability of amino acids and lipids before the mTOR 
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checkpoint but also underscores the importance of these factors being available before 
further progression can occur. 
 
Figure 1.2: Distinct nutrient checkpoints in G1 (A-D) BJ-hTERT cells were plated in DMEM 
containing 10% FBS. After 24 hrs. media was replaced with complete media (CM) or the 
indicated first block media conditions for 48 hrs. After the 48 hr. period media was replaced with 
24 hrs. of indicated media conditions plus radiolabeled thymidine for 24 hrs. After this 24 hrs. 
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period, cells were collected and thymidine incorporation was measured. (F) Mapped nutrient 
checkpoints in late G1. (Patel et al., 2017) 
 
 
Figure 1.3: mTORC1 and mTORC2 complexes and downstream substrates (Foster and 
Fingar, 2010) 
 
mTOR exists in 2 complexes mTORC1 and mTORC2, each distinguishable by 
their distinct components and downstream targets. mTORC1 consists of mTOR, the 
catalytic subunit; regulatory-associated protein of mTOR (Raptor); mammalian lethal 
with Sec13 protein 8 (mLST8); Proline-rich Akt substrate 40 kDa (PRAS40); and DEP-
domain-containing mTOR-interacting protein (Deptor) (Figure 1.3). These protein 
subunits play roles in regulating mTOR activity, assembly and localization. Activation of 
mTROC1 is most commonly measured by the level of downstream phosphorylation of 
its targets S6 Kinase 1 (S6K) and eIF-4E-binding protein 1 (4EBP1). Activation of S6K 
leads to phosphorylation of S6 ribosomal protein and hence protein synthesis at the 
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ribosome. Phosphorylation of 4EBP1 on the other hand is an inhibitory phosphorylation 
that inhibits 4EBP1 translation repressor activity (Fingar and Blenis, 2004).  
Activation of mTORC1 has been well studied and the current understanding is 
that amino acid availability plays a role in the recruitment of mTORC1 to its site of 
activation, the lysosome (Angarola and Ferguson, 2019; Bar-Peled and Sabatini, 2014). 
Specifically, amino acid induced activation of the Ras-related GTP binding proteins 
(Rags) leads to recruitment of mTOR to the lysosomal surface where it can be activated 
by the GTPase Rheb. Rheb activity is regulated by Tuberous Sclerosis Complex 2 
(TSC2). Upstream growth factor signaling causes TSC2 to be inactivated, enabling 
Rheb activation. It is therefore, the combined effects of amino acids and growth factors 
that allows for mTORC1 activation at the lysosome and phosphorylation of its 
downstream targets S6K and 4EBP1 (Figure 1.4).  
 




How mTOR senses all amino acids is still not fully understood but there has been 
research to show that there exist certain amino acids sensors upstream of mTOR 
activation at the lysosome (Wolfson and Sabatini, 2017). Sestrin 1 and 2 were identified 
as leucine sensors. They function by binding the mTOR inhibitor GATOR2 under 
leucine deprived conditions and dissociating upon leucine replenishment. CASTOR1 
also inhibits GATOR2 but under arginine starvation. Lastly, SAMTOR is a protein 
identified to relay methionine availability upstream of mTOR (Chantranupong et al., 
2014; Gu et al., 2017) (Figure 1.5). 
 
Figure 1.5: Leucine and Arginine sensors SESTRIN2 and CASTOR1 inhibit GATOR2 




Our lab has shown that in addition to amino acids, mTOR can also sense lipid 
availability. Menon et al. has shown that exogenously supplied fatty acids can induce 
activation of both mTOR complexes. This work was done in KRAS mutant cancer cells, 
known to be excellent scavengers of extracellular lipids. The mechanism by which 
extracellular lipids, specifically oleic acid (OA), activates mTOR is thought to be through 
OA induced de novo synthesis of phosphatidic acid (PA), a precursor to phospholipid 
synthesis (Figure 1.6). PA binds the FRB (FK506-binding protein–12-rapamycin-
binding) domain of mTOR, stabilizing it and thereby allowing for activation of both 
mTOR complexes. Knocking down key enzyme Lysophosphatidic acid acyl-transferase 
β (LPAAT-β) which is responsible for the acylation of LPA needed for synthesis of PA, 







Figure 1.6: Oleic acid activates mTOR through LPAAT-β-generated PA (A) Oleic acid 
incorporation into Phosphatidic Acid. (B) Knocking down LPAAT-β in Calu-1 cells diminishes 





Competence and Progression model  
 
Figure 1.7: Competence and Progression Model. Passage through Early G1 requires PDGF 
to avoid exit into G0. Late G1 progression requires IGF-1 as well as additional nutrient factors 
found in serum. 
 
The importance of mTOR activation prior to S phase entry was what led us to 
investigate its role in the competence and progression model of the cell cycle proposed 
by Pledger and Stiles in the late 1970s (Stiles et al., 1979). In this model they proposed 
that cells become competent to complete G1 and enter S phase when PDGF is made 
available for an amount of time at the start of G1, but will only actually progress on to S 
phase with the availability of IGF-1 later in G1 (Fig. 1.7). 
They show that quiescent BALB/c 3T3 human fibroblast cells need to be primed 
with as little as one hour with PDGF after which they can be shifted to platelet poor 
plasma (plasma deficient in PDGF) and still enter S phase. If these cells that were 
primed with PDGF were then shifted to plasma from hypophysectomized rats (plasma 
deficient in IGF-1) they lost their ability to enter S phase. Addition of IGF-1 to the 
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hypophysectomized rat plasma was able to restore their ability to enter S and replicate 
DNA. However, they noted that providing IGF-1 alone was insufficient and that other 
components of serum were needed for this progression to occur (Fig. 1.8). Given our 
finding of a lipid mediated checkpoint late in G1 and fatty acids’ ability to activate mTOR, 
we initially predicted that mTOR activation via uptake of extracellular fatty acids found in 
serum could promote progression late in G1.  
 
 
Figure 1.8: IGF-1 and serum factors are needed for progression of arrested BALB/c 3T3 
cells (A) BALB/c 3T3 cells were density arrested then exposed to purified PDGF for 3 hrs. After 
3 hrs. PDGF media was washed and replaced with plasma from hypophysectomized rats (●) or 
normal rats (○) plus radiolabeled thymidine. (B) Density arrested cells were treated with PDGF 
for 3 hrs., washed, then treated with plasma from hypophysectomized rats (○), plasma from 
hypophysectomized rats plus somatomedin C (IGF-1) (●), or pure somatomedin c (◊). Labeled 






Serum Factors  
In an in-vitro system we supply cells with the necessary nutrients through the use 
of a base medium supplemented mainly with human or animal serum. The medium itself 
typically contains varying amounts of amino acids and glucose while the serum is the 
cells’ source for growth factors and lipids, as well as containing other proteins such as 
globulins, fibrinogen and albumin.  
Uptake of nutrients can involve specific receptors and transmembrane 
transporters as in the case of growth factors and amino acids, or endosomal pathways 
that allow for less specific bulk uptake as would be the case with lipids and other 
extracellular proteins. The latter method includes macropinocytosis which involves 
membrane folding and pinching off into endosomal compartments which can then travel 
to various parts of the cell, including the lysosome, for cargo degradation (Commisso et 
al., 2013; Palm et al., 2015). 
Contrary to our initial belief that extracellular fatty acids may be an important late 
G1 progression factor, the preliminary findings of this investigation showed that uptake 
of a fatty acid carrier, the protein albumin, may be the crucial element for late G1 
progression in normal human fibroblasts. Albumin makes up approximately 50-60% of 
human and bovine serum, making it the most abundant protein in serum. It is a small 
globular protein whose function ranges from being a transporter protein that binds 
efficiently to hormones, fatty acids and ions to regulating osmotic pressure of the blood 
(Merlot et al., 2014).  
Research shows that under nutrient deprived conditions, cells can take up 
extracellular protein such as albumin to be trafficked to the lysosome for degradation 
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into free amino acids (Figure 1.9). These amino acids are used for further protein 
synthesis and growth (Palm et al., 2015). Studies have also shown that albumin 
accumulates very well in the tumor interstitium. In animal cancer models, injected 
labeled albumin is found to significantly accumulate in solid tumors (Merlot et al., 2014).    
Surprisingly, though we demonstrate that uptake of albumin is the crucial 
element in late G1 progression, this seems to be the case even in amino acid replete 
conditions making the purpose of albumin uptake something other than simply a source 






Figure 1.9: Extracellular protein degradation. Lysosomal degradation of extracellular protein 

































BSA stimulates the progression of fetal bovine serum (FBS)-primed BJ-hTERT 
human fibroblasts from G0 into S-phase 
In the absence of serum growth factors, cycling non-transformed cells exit the 
cycle and enter a state of quiescence referred to as G0. Restoring serum growth factors 
can stimulate quiescent cells to reenter the cell cycle and proceed to S-phase where the 
genome is replicated and then to Mitosis (Saqcena et al., 2013). As discussed in the 
Introduction, the process of reentry and progression can be broken up into two distinct 
stages –commitment and progression (Pledger et al., 1977; Stiles et al., 1979). 
Commitment could be achieved with as little as 1 hour treatment with PDGF; whereas, 
progression was more complicated involving IGF-1 and other undetermined factor(s) in 
serum (Pledger et al., 1977; Stiles et al., 1979). We recently identified a late G1 cell 
cycle checkpoint that monitored the presence of fatty acids (Patel et al., 2017).  
We therefore wanted to determine whether the lipids in serum contribute to late 
G1 cell cycle progression into S-phase. We used the human fibroblast cell line BJ-
hTERT, which arrests very well in G0 when deprived of serum (Saqcena et al., 2013). 
BJ-hTERT cells were put in serum-free medium for 48 hours, at which time all cells 
were treated with 10% FBS for 3.5 hrs. to prime the BJ-hTERT cells back into G1. At this 
point the cells were washed and then treated with medium containing [3H]-TdR without 
FBS (-FBS) and with FBS (+FBS) for 24 hrs. As shown in Figure 2.1 (columns 1 and 2), 
FBS-primed cells shifted to medium lacking FBS incorporated approximately 20% as 
much [3H]-TdR as the cells that were put back into medium containing 10% FBS. This 
result demonstrates that the 3.5 hrs. treatment was not sufficient to promote 
progression to S-phase where [3H]-TdR gets incorporated into DNA. To determine 
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whether FAs could promote the progression of FBS-primed BJ-hTERT cells into S-
phase we added a mixture of FAs along with fatty acid-free BSA carrier protein for the 
lipids (FA + BSA). We also added the FAs (FA) and BSA (BSA) separately (Figure 2.1 
(columns 3-5). These data were very surprising in that 0.05% BSA stimulated [3H]-TdR 
incorporation to the same extent as FBS. The FAs by themselves had little or no effect 
on [3H]-TdR incorporation, nor did it enhance the impact of the BSA on [3H]-TdR 
incorporation. We next performed a dose curve for the ability of BSA to induce [3H]-TdR 
incorporation in FBS-primed BJ-hTERT cells from 0.5% to the physiological 
concentration of albumin in circulating plasma of 3% (Ibrahim et al., 2020). As shown in 
Figure 2.1b, when the BSA concentration reached 3%, there was a 4-fold greater [3H]-
TdR incorporation than in the BJ-hTERT cells primed with and treated with FBS. These 
data surprisingly demonstrate that quiescent fibroblasts primed for 3.5 hrs. with FBS 
can be induced to progress into S-phase more effectively by BSA than by treating with 
FBS for the entire period of observation. Importantly, progression into S-phase was 




Figure 2.1: BSA stimulates the progression of FBS-primed BJ-hTERT from G0 into S-
phase. (a) BJ-hTERT cells were plated at 30% confluency in DMEM 10% FBS. After 24 hrs., 
cells were shifted to DMEM 0% FBS for 48 hrs. After this, media was replaced with DMEM 10% 
FBS for 3.5 hrs. This media was washed off and replaced with DMEM (-FBS), DMEM 10% FBS 
(+FBS), DMEM + fatty acid mix/ fatty acid-free BSA (FA + 0.05% BSA), DMEM 0.05% BSA 
(0.05% BSA), and DMEM fatty acid mix (FA) for 24 hrs. Cells were also labeled with [3H]-TdR 
for the final 24 hrs. of treatment, after which they were collected and the incorporated label [3H]-
TdR was determined by scintillation counting. Relative [3H]-TdR incorporation is represented as 
counts per minute and normalized to the positive control +FBS which has been given a value of 
100%. Significance asterisks are compared with the control. The data is represented as mean ± 
SD and is the result of at least 3 independent experiments each consisting of two replicates per 
condition. (b) Cells were plated, starved of FBS, primed with +FBS media for 3.5 hrs. as 
explained in (a) before replacement of media with +FBS or indicated concentrations of BSA for 
24 hrs. Cells were also labeled with [3H]-TdR for the final 24 hrs. of treatment, after which they 
were collected and the incorporated [3H]- TdR was determined by scintillation counting. Relative 
[3H]-TdR incorporation is represented as counts per minute and normalized to the positive 
control +FBS which has been given a value of 100%. **, p≤0.01, ****, p≤0.0001. Not significant 
(ns) means p>0.05.  
 
Suppression of macropinocytosis inhibits progression into S-phase by both FBS 
and BSA 
The uptake of protein into cells involves endocytic processes such as 
macropinocytosis (Commisso et al., 2013). To validate that the BSA-induced 
progression into S-phase required macropinocytosis we treated these same cells with 5-
(N-ethylN-isopropyl) amiloride (EIPA), which blocks macropinocytosis (Commisso et al., 
2013; Salloum et al., 2014). As shown in Fig. 2.2a, EIPA blocked progression into S-
phase by both BSA and FBS. These data suggest not only that BSA requires 
macropinocytosis, but that FBS-induced S-phase progression similarly requires uptake 
of protein. To demonstrate that the result is not simply an artifact of EIPA treatment, and 
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that uptake of protein is needed independent of growth factor activated pathways like 
PI3K/ AKT, we examined the impact of EIPA on the phosphorylation of AKT at the 
mTORC2 site at S473, which is very growth factor responsive (Toschi et al., 2009). As 
shown in Figure 2.2b, EIPA had no impact on the levels of AKT phosphorylation in cells 
treated with either BSA or FBS. These data demonstrate that EIPA is not exerting its 
effects by interfering with the transduction of intracellular signals. The data also suggest 
that macropinocytosis of proteins contained in FBS is critical for S-phase progression 
induced by serum. Since there are proteins other than albumin in FBS, we investigated 
whether other proteins could promote S-phase progression. We used human ᵧ-globulin 
alongside FBS to promote progression of FBS-primed BJ-hTERT into S-phase. As 
shown in Figure 2.2c, 3% ᵧ-globulin, like BSA, stimulated progression to S-phase more 
effectively than FBS. Thus, it appears that it is the protein in serum and BSA that is 
critical for promoting the S-phase progression of FBS-primed BJ-hTERT. Since albumin 
is the most abundant protein in serum (Ibrahim et al., 2020), it is likely that that the key 




Figure 2.2: Suppression of 
macropinocytosis blocks albumin-
induced cell cycle progression. (a) BJ-
hTERT cells were plated at 30% confluency 
in DMEM 10% FBS. After 24 hrs., cells were 
shifted to DMEM 0% FBS for 48 hrs. After 
this, media was replaced with DMEM 10% 
FBS for 3.5 hrs. This media was washed off 
and cells were treated with media conditions 
+FBS, +FBS + EIPA 75uM, 3% BSA, and 
3% BSA + EIPA 75uM for 24 hrs. Each final 
24 hrs. condition also contained [3H]-TdR. 
After 24 hrs., cells were collected and the 
incorporated [3H]-TdR was determined by 
scintillation counting. (b) Cells were plated 
and treated as in (a) after which cells were 
harvested and the levels of Akt 
phosphorylation at Ser473 was determined 
by Western blot analysis. (c) BJ-hTERT 
cells were plated, starved of FBS, primed 
with +FBS media for 3.5 hrs. as explained in 
(a) before replacement with media 
conditions -FBS, +FBS, 3% bovine serum  
globulin fraction. Each final 24 hrs. condition 
also contained [3H]-TdR. After 24 hrs., cells 
were collected and the incorporated label 
([3H]-TdR) was determined by scintillation 
counting. In both (a) and (c) relative [3H]-
TdR incorporation is represented as counts 
per minute and normalized to the positive 
control +FBS which has been given a value 
of 100%. Significance asterisks are 
compared with the control unless otherwise 
noted with brackets. The data is represented 
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as mean ± SD and is the result of at least 3 independent experiments each consisting of two 
replicates per condition. *, p≤0.05; **, p≤0.01; ***, p≤0.001. Not significant (ns) means p>0.05. 
 
The role of mTORC1 and insulin in the late G1 progression of FBS-primed BJ-
hTERT cells 
A key mediator of late G1 progression is mTORC1, which mediates a late G1 
checkpoint that is close to the G1 to S-phase transition site (Fingar et al., 2004; Planas-
Silva and Weinberg, 1997; Saqcena et al., 2013). mTOR has been referred to as an 
integrator of growth factor and nutrient signals for cell cycle progression (Dibble and 
Manning, 2013; Zoncu et al., 2011). We therefore examined the effect of insulin, which 
is a strong inducer of mTORC1 (Yoon, 2017) on the S-phase progression of FBS-
primed BJ-hTERT cells. As shown in Figure 2.3a, insulin was unable to increase [3H]-
TdR incorporation in the FBS-primed BJ-hTERT cells. We also examined the effect of 
the mTORC1 inhibitor rapamycin on the ability of FBS and BSA to induce [3H]-TdR 
incorporation in FBS-primed BJ-hTERT cells. As shown in Figure 2.3a, rapamycin 
inhibited both FBS- and BSA-induced S-phase progression as indicated by [3H]-TdR 
incorporation. We next compared the effect of FBS, BSA and insulin on mTOR activity 
as indicated by phosphorylation of S6K (mTORC1) and Akt (mTORC2).  
As with the [3H]-TdR incorporation experiment, cells were starved of serum for 48 
hrs., primed with FBS and then washed and treated with, -FBS media, 10% FBS, BSA, 
or insulin or for 30 minutes. As shown in Figure 2.3b, 30 min treatment with -FBS media 
resulted in a significant decrease in S6 kinase and Akt phosphorylation. Treatment with 
either FBS or insulin sustained elevated levels of phosphorylated S6K and 
phosphorylation of Akt at the mTORC2 site at Ser473. In contrast, removal of FBS and 
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subsequent treatment with BSA resulted in weakly elevated phosphorylation of S6K and 
Akt (Figure 2.3b). Rapamycin completely inhibited the phosphorylation of S6K induced 
by FBS and BSA.  
The data in Figure 2.3 reveal that in spite of a strong activation of mTORC1, 
insulin by itself, could not induce progression of primed BJ-hTERT cells into S-phase. In 
contrast, the presence of BSA sustained lower, but significant levels of mTORC1 activity 
while strongly promoting progression of primed BJ-hTERT cells into S-phase. 
Importantly, the induction of S phase progression by BSA was suppressed by 
rapamycin. These data indicate that mTORC1 is necessary for S-phase progression in 
response to both FBS and BSA, but not sufficient as demonstrated by the strong 
induction of mTORC1 and the lack of induction of S-phase progression by insulin.  
 
Figure 2.3: The role of mTORC1 and insulin in the late G1 progression of FBS-primed BJ-
hTERT cells. (a) BJ-hTERT cells were plated at 30% confluency in DMEM 10% FBS. After 24 
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hrs., cells were shifted to DMEM 0% FBS for 48 hrs. After this, media was replaced with DMEM 
10% FBS for 3.5 hrs. This media was washed off and cells were treated with conditions -FBS, 
+FBS, 3% BSA, DMEM + Insulin 10uM (Insulin), DMEM 10% FBS + Rapamycin 20uM (+FBS + 
Rapa) and DMEM 3% BSA + Rapamycin 20uM (BSA + Rapa) for 24 hrs. Each final 24 hrs. 
condition also contained [3H]-TdR. After 24 hrs., cells were collected and the incorporated [3H]-
TdR was determined by scintillation counting. Relative [3H]-TdR incorporation is represented as 
counts per minute and normalized to the positive control +FBS which has been given a value of 
100%. Significance asterisks are compared with the control unless otherwise denoted with 
additional brackets. The data is represented as mean ± SD and is the result of at least 3 
independent experiments each consisting of two replicates per condition. (b) As described in 
(a), cells were plated, deprived of FBS for 48 hrs. then primed with +FBS for 3.5 hrs. After this, 
media was replaced with conditions indicated for 30 min. After 30 minutes cells were harvested 
and protein levels determined by Western blot analysis. *, p≤0.05, ****, p≤0.0001. Not significant 
(ns) means p>0.05. 
 
BSA treatment allows for one cell division of the BJ-hTERT cells followed by cell 
death  
The data in Figures 2.1 and 2.2 demonstrate that BSA and perhaps other 
proteins contained in serum are driving FBS-primed BJ-hTERT fibroblasts into S-phase. 
We wished to determine whether these cells actually undergo mitosis and division. The 
FBS-primed cells were treated with FBS, BSA and insulin for 24 hrs. at which time the 
number of viable cells remaining on plates was determined. As shown in Figure 2.4a 
there was an increase in cell number in the cells treated with FBS and BSA. There was 
no increase in cell number seen in cells treated with insulin nor was there elevated 
numbers in the FBS- and BSA-treated cells if rapamycin was included (Figure 2.4a). 
However, if the cells were maintained in BSA for 4 days, the cells were mostly dead 
(Figure 2.4b). Thus, while the cells were able to undergo one cell division, once faced 
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with  the decision to restart the cycle the lack of growth factor in the BSA condition did 
not result in exit into G0 at the Restriction point, rather this ultimately led to cell death.  





hTERT cells were 
plated at 30% 
confluency in 
DMEM 10% FBS. 
After 24 hrs., cells 
were shifted to 
DMEM 0% FBS for 48 hrs. After this, media was replaced with DMEM 10% FBS for 3.5 hrs. 
This media was washed off and cells were treated with media conditions -FBS, +FBS, 3% BSA, 
DMEM + Insulin 10uM (Insulin), DMEM 10% FBS + Rapamycin 20uM (+FBS + Rapa) and 
DMEM 3% BSA + Rapamycin 20uM (BSA + Rapa) for 24 hrs. After 24 hrs., viable adherent 
cells were collected and counted with a hemocytometer. (b) Cells were plated and treated as 
described in (a). After 24 and 96 hrs., viable (attached) cells were collected and counted with a 
hemocytometer. In both (a) and (b) cell number is represented as percent of positive control 
+FBS which has been given a value of 100%. Significance asterisks are compared with the 
control unless otherwise denoted with additional brackets. The data is represented as mean ± 
SD and is the result of at least 3 independent experiments. *, p≤0.05, ***, p≤0.001. Not 
significant (ns) means p>0.05. 
 
Effect of amino acids on mTORC1 activity and cell cycle progression 
Bar-Sagi and colleagues reported previously that macropinocytosis of protein is 
an amino acid supply route in Ras-transformed cells under amino acid deprived 
conditions (Commisso et al., 2013). In this study, the medium contained the standard 
amino acid levels of DMEM. Thus, it is unlikely that it was the amino acids generated 
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from BSA that was driving the FBS-primed BJ-hTERT cells into S-phase. However, 
seeing as amino acids are known to contribute to the activation of mTORC1, an 
important regulator of cell cycle progression from late G1 into S-phase (Avruch et al., 
2009; Efeyan et al., 2012; Saqcena et al., 2013) we chose to look at the effect on 
mTORC1 activity of adding additional amino acids to FBS-primed BJ-hTERT cells. As 
shown in Figure 2.5a, the addition of amino acids did increase the levels of 
phosphorylated S6K. However, amino acids had no impact on progression to S-phase 
as determined by incorporation of [3H]-TdR (Figure 2.5b). Thus, the generation of amino 
acids from BSA does not explain the ability of BSA to drive FBS-primed BJ-hTERT cells 
into S-phase.  
Figure 2.5: Effect of BSA and 
amino acids on cell cycle 
progression and mTORC1 
activity. (a) BJ-hTERT cells were 
plated at 30% confluency in MEM 
10% FBS. After 24 hrs., cells were 
shifted to MEM 0% FBS for 48 hrs. 
After 48 hrs., media was replaced 
with MEM 10% FBS for 3.5 hrs. This 
media was washed off and cells 
were treated with media conditions -
FBS, 3% BSA, and MEM with amino 
acid concentrations as indicated for 
24 hrs. The next day cells were 
harvested and protein levels 
determined by Western blot 
analysis. (b) As described in (a), 
cells were plated, deprived of FBS 
for 48 hrs. and then primed with 
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+FBS for 3.5 hrs. This media was washed off and replaced with conditions indicated for 24 hrs. 
Each final 24 hrs. condition also contained [3H]-TdR. After this 24 hrs. treatment, cells were 
collected and the incorporated label ([3H]-TdR) was determined by scintillation counting. 
Relative [3H]-TdR incorporation is represented as counts per minute and normalized to the 
positive control MEM1X which has been given a value of 100%. ****, p≤0.0001. Not significant 
(ns) means p>0.05. 
 
Albumin affects rate of progression in KRAS mutant cells  
Under our experimental conditions we have shown that physiologic levels of 
albumin led to more DNA synthesis than typical cell culture conditions of 10% FBS, 
suggesting an increase in the rate of progression with albumin. Based on our findings 
and given the importance of G1 regulation in cancer, we found it important to investigate 
the effects that albumin may have on the rate of cycle progression in cancer cells. Thus 
far we have preliminary data suggesting that albumin may have a similar effect on the 
rate of G1 progression in cancer cells as well. We chose to use MDA-MB-231 cells 
seeing as they are excellent scavengers of extracellular nutrients, upregulating 
macropinocytosis as a way to fulfill the high energy demands of the cell (Commisso et 
al., 2013; Palm et al., 2015). It's known that in response to amino acid deprivation these 
cells take up albumin for amino acids but we wondered whether or not albumin may still 
have an effect on their rate of progression in amino acid replete conditions as we saw in 
BJ-hTERT cells.  
It's important to note that unlike the BJ-hTERT cells whose progression through 
G1 can be halted with as little as 24hrs. of growth factor or serum deprivation, allowing 
us to test albumin’s effects on restarting progression, this is not the case in 231 cells. 
231 cells do not exhibit a rapid a drop in DNA synthesis to suggest G1 arrest, 
presumably due to constitutively active RAS which can fulfill the growth factor 
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requirement (Blagosklonny and Pardee, 2002). Instead, we have seen in the past that 
serum deprivation in 231 cells does lead to cell death over a course of days due to 
deprivation of lipids found in serum (Salloum et al., 2014). The cells’ inability to 
upregulate expression of a key enzyme in the formation of monounsaturated fatty acids, 
Stearoyl-CoA desaturase-1 (SCD1), makes them particularly vulnerable to lipid 
deprivation from serum withdrawal.   
This lack of lipid does not cause an acute arrest in G1, rather the cells keep 
progressing in these conditions to their own detriment, evident from decreased cell 
viability and cleaved caspase levels (Salloum et al., 2014). Therefore, similar to the 
experiments with the BJ-hTERT cells, we subjected the 231s to serum deprivation for 
48 hrs. followed by a 24hrs. treatment period with albumin to see if albumin would have 
any positive influence on the rate of progression in the surviving cell population. Any 
increases in thymidine incorporation would reflect changes in rate of progression in 
surviving cells, not albumin’s ability to rescue cell death or restart cycle progression 




Figure 2.6: Albumin increases rate of progression in serum starved MDA-MB-231 cells. 
BJ-hTERT and MDA-MB-231 cells were starved of serum for 48 hrs. After this, media was 
replaced with DMEM 10% FBS for 3.5 hrs. This media was washed off and replaced with 
DMEM (No Serum), DMEM 10% FBS (Serum) or DMEM 3% BSA (3% BSA) for 24 hrs. plus 
radiolabeled thymidine. Thymidine incorporation was measured after 24 hrs. treatment period. 
Number of adherent cells were also counted after 24 hrs. and 96 hrs. of treatment. 
 
What we found was a trend very similar to our previous experiments where 
deprivation of serum caused very little thymidine incorporation. However, with the 
addition of albumin we were able to see an even greater rate of synthesis than even the 
control condition (Figure 2.6). This suggests that in 231 cells albumin is able to increase 
the rate of progression into S phase as well. The striking difference was that unlike BJ-
hTERT cells which undergo an increase in DNA synthesis and complete the cycle as is 
evident from an increase in cell number after the treatment period of 24 hrs., 231 cells 
have an increase in thymidine incorporation but a decrease in overall viable cells. The 
increase in rate of progression seems to lead to cell death faster, even more so than 
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just having a lack of serum which we can see from a significantly lower number of cells 
after treatment with delipidated serum + albumin v. delipidated serum alone (Figure 
2.7).  
 These results are important as they suggest 
albumin’s progression effects to not be limited to BJ-
hTERT cells alone. Additionally, if increasing the 
rate of G1 to S progression with albumin under 
nutrient deprived conditions like lipid deprivation, 
can significantly increase cell death in KRAS mutant 
cells, then using fatty acid transporter inhibitors 
conjugated to albumin may prove even more 
effective than other methods of drug delivery alone. 
However, additional experiments and replicates of 
conditions are needed. 
Figure 2.7: Addition of albumin to delipidated serum increases cell death in MDA-MB-231 
cells. MDA-MB-231 cells were plated in DMEM 10% delipidated serum and DMEM 10% 
delipidated serum 3% BSA for 24 hrs. After 24 hrs. adherent cells were collected and counted.  


































Based on a recent study from our lab where we identified a late G1 lipid 
checkpoint (Patel et al., 2017), we began an investigation to determine whether lipids 
could drive cells into S-phase. From quiescence, 3.5 hrs. of FBS treatment primes cells 
for progression, but cells do not go to S-phase and begin DNA synthesis. Surprisingly, 
we found that while lipids did not facilitate progression to S-phase, the albumin protein 
promoted progression of FBS-primed BJ-hTERT fibroblasts into S-phase. 3% albumin 
treatment seemed to actually increase the rate of progression as well, causing a four-
fold greater increase in thymidine incorporation than 10% FBS treatment.  
Although albumin allowed for weakly sustained mTORC1 activity, the albumin-
induced progression of FBS-primed BJ-hTERT cells into S-phase was inhibited by 
rapamycin – indicating that mTORC1 is required. Although insulin strongly induced 
mTORC1 activity, it was not sufficient to promote the progression of FBS-primed 
fibroblasts into S-phase. Insulin and IGF-1 provide critical growth factor input in late G1 
where both growth factor and nutrient signals are integrated by mTORC1 (Dibble and 
Manning, 2013; Fingar and Blenis, 2004). In this regard, the ability of FBS to promote 
the progression of FBS primed cells was blocked by EIPA, which suppresses 
macropinocytosis of other extracellular components found in serum (Commisso et al., 
2013). The EIPA treatment had no impact on the high levels of AKT phosphorylation, 
suggesting that the lack of progression was not due to EIPA’s effects on growth factor 
signaling. Rather, the drug’s ability to block S-phase progression was due to something 
in FBS that is brought into the cells by macropinocytosis – like albumin, a small globular 
protein that comprises the largest percentage of serum protein in the body. These data 
demonstrate that for cells in G0 / quiescence, a 3.5 hrs. treatment with FBS was all the 
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growth factor treatment needed in that BSA was sufficient to promote progression to S-
phase without growth factors present in the latter part of G1. The sensitivity to 
rapamycin indicated a growth factor-independent mTORC1 requirement.  
The ability to promote the progression of FBS-primed BJ-hTERT cells into S 
phase was not likely due to the generation of amino acids from the BSA as was 
reported for Ras-transformed cells (Commisso et al., 2013). This is because standard 
concentrations of amino acids were present in the medium used for these studies and 
additional amino acid supplementation into the media did not induce S phase entry. 
Progression into S phase was also not restricted to albumin. Gamma-globulins found 
within serum could also promote S-phase progression of the FBS-primed BJ-hTERT 
cells. Thus, the effects reported here were apparently due to a high concentration of 
protein in the culture medium that gets taken up by macropinocytosis and is not 
dependent on individual amino acids. 
 These results indicate that protein is providing something that free exogenous 
amino acids cannot. We are proposing that while having adequate concentrations of 
amino acids present, it is difficult for the cell to determine whether there are adequate 
concentrations of all 20 amino acids. mTORC1 responds to some, but not all amino 
acids (Wolfson and Sabatini, 2017). To date, there have been a handful of amino acid 
sensors identified, all of which ultimately allow for mTOR activation. However, the 
presence of a high concentration of protein in serum would be a much broader indicator 
that there is an adequate supply of all 20 amino acids. The abundance of amino acids 
also ensures adequate precursors for nucleic acids and fatty acids. Since albumin is the 
34 
 
most abundant protein in serum (Ibrahim et al., 2020), it is likely the most physiologically 
relevant protein for facilitating progression from G1 into S-phase.  
A recent report using cancer cells reported that serum-starved HepG2/C3A 
hepatocellular carcinoma cells could be induced to progress from G1 into S-phase if 
treated with BSA (Ibrahim et al., 2020). The major difference being that the cancer cells 
did not need priming with growth factors. Since the cells used in this study were cancer 
cells it is unclear whether these cells were exiting the cell cycle upon serum deprivation. 
However, cyclin D1 levels were not significantly reduced under serum starved 
conditions suggesting that the cancer cells, as expected, were not going into 
quiescence where cyclin D1 levels are reduced in non-transformed cells (Saqcena et 
al., 2013). Thus, while the conditions for cell cycle progression from G1 into S-phase 
differ from conditions in our study, this work provides further evidence that albumin can 
promote late G1 to S-phase cell cycle progression in the absence of growth factors. 
Considering what we know about growth factor signaling being crucial for cyclin 
transcription and CDK activation, we initially looked at levels of cyclin D1 and Rb 
phosphorylation following BSA treatment (data not shown). There were no significant 
differences in the levels between BSA treatment and no BSA (-FBS) treatment which 
was not all too surprising seeing as in both cases cells were first primed with whole 
serum media for 3.5 hrs. This priming period could have been sufficient to allow for 
hypo-phosphorylation of Rb and subsequent hyper-phosphorylation that was sustained 
throughout the following treatment period. In fact, Yao and colleagues show that with 
sufficient serum stimulation, E2F release from Rb can be sustained even without 
continuous serum availability thereafter (Yao et al., 2008). However, despite a similar 
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cyclin and P-Rb profile, we see that the presence of BSA was needed for DNA 
synthesis to occur.       
While it remains unclear as to the exact mechanism for albumin-driven cell cycle 
progression into S phase, the sensitivity to EIPA implicates macropinocytosis and 
vesicle trafficking of albumin to the lysosome. The lysosome is also where mTORC1 
functions as a nutrient sensor for both amino acids and lipids (Efeyan et al., 2015; Frias 
et al., 2020; Menon et al., 2017). Consistent with the convergence of both albumin and 
mTORC1 on the lysosome and the sensitivity of albumin-induced cell cycle progression 
to rapamycin, it is likely that the lysosome plays a role in albumin induced progression 
of FBS-primed BJ-hTERT fibroblasts into S-phase. 
Interestingly, albumin’s effects on progression were also seen in KRAS mutant 
MDA-MB-231 cells. Under serum starved conditions, we suspect that albumin may be 
increasing rate of progression into S phase but this does not lead to completion of the 
cycle. Rather the increased cell death may be due to inability to upregulate fatty acid 
synthesis when in G2/M, a critical time for phospholipid membrane growth, and 
ultimately results in early apoptosis. This may have therapeutic implications seeing as 
drugs used to target fatty acid transporters may be able to compromise cancer cell 
health more effectively if conjugated with albumin, known to accumulate in the tumor 
































Aside from its function as a transport protein we show here that albumin may 
possibly serve as a crucial progression signal needed for late G1 to S phase entry. The 
effects of albumin seem to be independent of growth factor availability late in G1 and 
independent of general amino acid availability in the cell. We speculate that uptake of 
extracellular protein such as albumin may signal to the cell, variety as opposed to 
abundance of amino acid and in doing so facilitates progression.  
 The exact mechanism of how the cell senses albumin as a source of amino acid 
independent of further mTOR activation remains unanswered. Experiments to trace 
albumin trafficking under these conditions would shed more light on whether the 
continuation of the cycle relies on degradation of the albumin within the lysosome or 
sensing the whole protein upstream of degradation.  
 Degradation of albumin within the lysosome has been reported to give rise to 
many bioactive peptides and biomarkers for disease (Kragh-Hansen, 2018). Studies 
have identified and sequenced bioactive peptides derived from human serum albumin 
(HSA) found in various body fluids. These same fragments of HSA could be produced 
by plasma proteases when dropping plasma pH to more acidic levels like that found 
within lysosomes. Additionally, secretion of lysosomal proteases by malignant tumor 
cells into the extracellular space can result in the formation of an HSA derived fragment 
known to interact with cell surface receptors. One particular peptide was reported to 
function as a biomarker for prostate cancer (Mohr et al., 2015; Tao et al., 2019). 
Exposing albumin to plasma proteases at low pH and monitoring the effects that the 
resulting fragments have on cell cycle progression would be of interest.  
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Another explanation for the effects we see with albumin could be due to the 
conditions of our experiment causing cells to favor whole protein over free amino acid in 
the media. There is the possibility of reduced levels of amino acid import into the cell via 
amino acid transporters in the absence of growth factor signaling. Research has shown 
that expression of cell surface amino acid transporters can rely on Akt dependent 
activation of mTOR (McCracken and Edinger, 2013). This could be one explanation as 
to why under our BSA treatment condition which is devoid of serum, whole protein 
uptake and degradation would be the preferred method for increasing intracellular 
amino acid levels under complete serum starvation. Experiments looking at isotope 
labeled amino acid transport across the cell membrane and into the lysosome under our 
conditions would be necessary. 
   Our preliminary data with albumin treatment in KRAS mutant cancer cells 
suggests albumin’s progression effects to not be limited to BJ-hTERT cells alone. 
Albumin may be increasing rate of progression into S phase in MDA-MB-231 cells as 
well. If increasing the rate of G1 to S progression with albumin under nutrient deprived 
conditions like lipid deprivation, can significantly increase cell death in these cells, then 
using fatty acid transporter inhibitors conjugated to albumin may prove even more 
effective than other methods of drug delivery alone. However, much remains to be 
answered as to how albumin can cause such a progression through late G1 especially 
given the fact that it has not been shown to be involved in any signaling pathways 
































Cells and cell culture conditions and cell viability  
The BJ-hTERT cell line used in this study was obtained from American Type Culture Collection. 
No authentication was performed by the authors. Cell lines were maintained in Dulbecco's 
modified Eagle's medium (DMEM) (Sigma) supplemented with 10% fetal bovine serum (FBS) 




Reagents were obtained from the following sources. Antibodies against S6K (9202), PS6K T389 
(9234), P-AKT S473 (9272), and GAPDH (5174) were obtained from Cell Signaling Technology; 
anti mouse- and anti-rabbit HRP-conjugated secondary antibodies were obtained from 
Proteintech. Fatty acid mixture (11905) was obtained from Invitrogen, and fatty acid free bovine 
serum albumin (A9205) was obtained from Sigma. Rapamycin (R-5000) was obtained from LC 
Laboratories. Ultima Gold scintillation fluid (6013681) and [3H]-thymidine deoxyribose ([3H]-TdR) 
(20 Ci/mmol, 1 mCi/ml) (NET-027E) were obtained from PerkinElmer. DMEM (D6429) high 
glucose, MEM (M4655) and MEM Amino acids (50x) solution (M5550) was obtained from 
Sigma. Insulin (I9278), EIPA and Human Globulin fraction (G3637) were obtained from Sigma. 6  
 
Lipid mix supplementation  
A fatty acid mix was obtained from Invitrogen (11905) and supplied to cells as a 1:200 dilution 
complexed with 10% BSA (Sigma) in a 2:1 ratio for the final concentration of lipids in the 







Thymidine incorporation assay  
Cells were labeled with 1 Ci/ml [3H]-TdR. At the indicated times, cells were washed twice with 1 
ml of phosphate-buffered saline, and then precipitated twice with 1 ml of 10% trichloroacetic 
acid. The precipitates were solubilized in 0.5 ml of 0.5% SDS, 0.5 M NaOH solution, and the 
extent of [3H]-TdR incorporation was quantified using 75 ul of sample and 3 ml of scintillation 
fluid.  
 
Western blot analysis 
Proteins were extracted from cultured cells in M-PER (Thermo Scientific 78501). Equal amounts 
of proteins were subjected to SDS-PAGE on polyacrylamide separating gels. Electrophoresed 
proteins were then transferred to nitrocellulose membrane. After transfer, membranes were 
blocked in an isotonic solution containing 5% nonfat dry milk in phosphate-buffered saline. 
Membranes were then incubated with primary antibodies 7 as described in the text. The 
dilutions were used as per vendor’s instructions. Depending on the origin of the primary 
antibody, either anti-mouse- or anti-rabbit HRP-conjugated IgG was used for detection using the 
ECL system (Kindle Biosciences 1002).  
 
Statistical analysis  
Statistical significance was analyzed using Graph Pad Prism 8 software. Comparisons between 
two sets of samples was made using unpaired t-tests. For multiple comparisons, an unpaired 
one-way analysis of variance (ANOVA) was performed. Data are plotted as the mean with 
standard deviation. The p-values are as follows: *, p≤0.05; **, p≤0.01; ***, p≤0.001; ****, 
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